U.S. Food and Drug Administration (FDA) approves a new drug said to cut death risk in heart patients by 20 percent
The news of the Food and Drug Administration's fast-tracked approval of a new heart failure drug by Novartis was met this week with unusually strong enthusiasm from the medical community. Named "Entresto", the new drug was hailed as a "breakthrough" by many.
"Heart failure is a leading cause of death and disability in adults," said Dr. Norman Stockbridge, M.D., Ph.D., director of the Division of Cardiovascular and Renal Products in FDA's Center for Drug Evaluation and Research. "Treatment can help people with heart failure live longer and enjoy more active lives.
FDA reported the most common side effects in clinical trial participants being treated with Entresto were low blood pressure, high blood potassium levels, and poor kidney function.
About 26 million people worldwide suffer from heart failure, a condition in which the heart is weakened and unable to pump enough blood and oxygen to a body's organs. It is usually caused by a heart attack or high blood pressure and tends to worsen over time.